eligibility_summary
Eligibility: Ages 2 to <35, newly diagnosed classical Hodgkin lymphoma confirmed by at least 2 tertiary centers, adequate organ function, informed consent. Exclusions: nodular lymphocyte-predominant HL, preexisting immunodeficiency (primary, transplant, or on systemic immunosuppressants) or HIV+, pregnant or breastfeeding, systemic corticosteroid use within 28 days.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests a PET/CT‑adapted regimen replacing vincristine/bleomycin with brentuximab vedotin (BV) in ABVE‑PC to form BV‑AEPC for newly diagnosed cHL (CAYA). Interventions and mechanisms: • Brentuximab vedotin—antibody–drug conjugate targeting CD30 on Hodgkin/Reed‑Sternberg cells, internalized to release MMAE (microtubule inhibitor) causing apoptosis, may invoke ADCC. • Doxorubicin—anthracycline/topoisomerase II inhibitor, DNA intercalation. • Etoposide—topoisomerase II inhibitor. • Cyclophosphamide—alkylating agent causing DNA crosslinks. • Prednisone—glucocorticoid inducing lymphocyte apoptosis. • Dacarbazine—alkylating/methylating agent (added if early non‑CMR). • Tislelizumab—anti‑PD‑1 monoclonal antibody restoring T‑cell function (± bedamustine, an alkylator) for late non‑CMR. • Response‑adapted radiotherapy, optional autologous SCT. Targets/pathways: CD30+ HRS cells, microtubules, DNA damage/crosslinking, topoisomerase II, PD‑1/PD‑L1 axis, glucocorticoid receptor.